PHASE II: DOXIL CYCLOPHOSPHAMIDE,VINCRISTINE & PREDNISONE:AIDS SYSTEMIC LYMPHOMA

第二阶段：DOXIL 环磷酰胺、长春新碱

• 批准号: 7378453
• 负责人: CHRISTOPHER EHMANN
• 金额: $ 0.29万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378453
• 关键词: PHASE; II; DOXIL; CYCLOPHOSPHAMIDE; VINCRISTINE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Drug therapy using liposomal encapsulation is a relatively new way of drug delivery that appears to enhance efficacy and tolerability of medications used to treat cancer. Doxil is a Doxorubicin formulation delivered this way. This study compares the efficacy and tolerability of Doxil in patients with Aids related systemic lymphoma with conventional doxorubicin-based chemotherapy.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。使用脂质体封装的药物治疗是一种相对较新的药物递送方式，似乎可以增强用于治疗癌症的药物的功效和耐受性。 Doxil 是一种通过这种方式输送的阿霉素制剂。本研究比较了 Doxil 与传统的基于阿霉素的化疗对艾滋病相关全身性淋巴瘤患者的疗效和耐受性。